The investigators propose to influence estrogen receptor (ER) signaling by combining
endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal
growth factor receptor 2 (HER2)+ early stage breast cancer.
Procedure: Breast surgery
Procedure: Research tumor biopsy
Procedure: Research bone marrow (OPTIONAL)
Procedure: Research blood sample
Genetic: Research blood for germline DNA
Procedure: Blood for detection of circulating tumor cells
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02907918
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal, staging criteria is to be based on AJCC 7.
Tumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization (WHO) criteria). Patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor size.
At least 18 years of age.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Normal bone marrow and organ function as defined below:
Leukocytes ≥ 3,000/mcL
Absolute neutrophil count ≥ 1,500/mcl
Platelets ≥ 100,000/mcl
Total bilirubin ≤ institutional upper limit of normal (IULN)
AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
Left ventricular ejection fraction (LVEF) ≥ 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)
Baseline corrected QT interval (QTcF) < 480 ms
Women of childbearing potential must agree to undergo pregnancy testing within 14 days of study entry and agree to use adequate contraception (barrier method of birth control, abstinence, not hormonal) prior to study entry and for the duration of study participation as well as chemical LHRH Agonist with goserelin. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Prior systemic therapy for indexed breast cancer.
Indeterminate or negative HER2 status.
Inflammatory breast cancer.
A history of other malignancy ≤ 5 years from diagnosis of indexed BC with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix.
Currently receiving any other investigational agents or received any within the past 28 days.
Know to be HIV positive.
Known hepatitis B or C infection.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort).
Any condition that impairs the ability to swallow or absorb oral medication (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affective absorption).
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
All locations for NCT02907918
United States (6)
Phoenix, Arizona, United States, 85054
Put me in touch!
Indiana University Health Melvin and Bren Simon Cancer Center
Bloomington, Indiana, United States, 46202
St. Elizabeth Physicians
Edgewood, Kentucky, United States, 41017
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Put me in touch!
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Put me in touch!
Doctor's Hospital of Laredo
Laredo, Texas, United States, 78041
not yet recruiting
View full eligibility
Tris trial is registered with FDA with number: NCT02907918. The sponsor of the trial is Washington University School of Medicine and it is looking for 48 volunteers for the current phase.
Official trial title: A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.